NanoViricides is trading at $1.43, down 5.30%, after its October 21 regular-session close at $1.51; no catalyst is confirmed. - An October 21 report noted a prospectus filing for a $2.375 million common-stock offering, but causation is unestablished. - October 20 positive juvenile-mouse safety findings for NV-387 preceded the drop; no link is evidenced. - Major indexes rose, so the supplied context does not point to broad-market weakness.